In a report released today, Robert Hazlett from BTIG maintained a Buy rating on Galera Therapeutics (GRTX – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $1.71.
Hazlett covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Seelos Therapeutics, and CTI BioPharma. According to TipRanks, Hazlett has an average return of -0.3% and a 32.46% success rate on recommended stocks.
Galera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Galera Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $16.03 million. In comparison, last year the company had a GAAP net loss of $16.81 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Read More on GRTX:
- Galera Therapeutics announces presentation of analysis of Phase 3 ROMAN trial
- Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
- Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
- Galera Therapeutics reports Q4 EPS (58c), consensus (54c)
